MAPT and Alzheimer disease: The concept of drug development in AD should be based on multi-target strategy such as Aβ42 deposition, Tau hyper-phosphorylation, oxidative stress as well as neuroinflammation, and insulin signaling impairment to achieve a marked amelioration in the memory process and prevent neurodegeneration.